Health
Trending

Saudi Arabia Teams Up with AstraZeneca to Strengthen Cardiac Care

The Saudi Heart Association is reinforcing its efforts to improve cardiovascular care through a new partnership with AstraZeneca, focusing on scientific research, medical training and better treatment for patients with hypertension.

The memorandum of understanding comes as cardiovascular disease continues to pose a significant public health challenge in the Kingdom, according to the Saudi Press Agency.

Figures from the General Authority for Statistics show that 7.9 percent of people aged 15 and over had hypertension in 2024, while 1.5 percent had cardiovascular disease.

Rewriting the Future of Heart Care

The World Health Organization (WHO) defines cardiovascular diseases as a group of disorders that affect the heart and blood vessels, including coronary heart disease and cerebrovascular disease, which affect the blood supply to the heart and brain.

Against this health backdrop, the new agreement sets out several areas of cooperation, starting with the generation of scientific evidence through cardiology studies and research, alongside greater scientific exchange through conferences and forums.

More broadly, the partnership will focus on developing the capabilities of healthcare practitioners in cardiac specialties and improving care for hypertension patients by supporting enhancements to cardiac care policies, quality standards, operational efficiency and treatment pathways across the Kingdom.

How Can Collaboration Raise Cardiac Care Standards?

Dr. Waleed Al-Habeeb, president of the Saudi Heart Association and a consultant heart failure cardiologist at King Saud University, highlighted the need for coordinated efforts across the healthcare system to promote heart disease treatment outcomes in the Kingdom.

He noted that the partnership with AstraZeneca would expand the association’s capacity to generate scientific evidence, strengthen healthcare professionals’ capabilities and improve cardiac care standards. Ultimately, these efforts would help more patients lead longer and healthier lives.

How Is Saudi Arabia Closing Gaps in Cardiac Care?

The Saudi Heart Association’s collaboration with AstraZeneca follows an earlier partnership aimed at strengthening cardiovascular disease prevention and early detection.

In 2024, the association signed an agreement with German pharmaceutical company Bayer to elevate cardiac care, with a particular focus on identifying people at risk of cardiovascular disease.

Bayer said that the initiative targeted individuals with a combination of risk factors, including high blood pressure, smoking, unhealthy diets and high cholesterol, as well as age and family history.

A Faster Path to Life-Saving Treatment

Alongside efforts to strengthen research and preventive care, Saudi Arabia has also reported improvements in the timely treatment of heart attacks.

At the Model of Care Forum in January 2025, Health Minister Fahad Al-Jalajel announced that the healthcare sector had achieved a 70 percent rate of heart attack treatment within the target timeframe in 2024.

For Al-Jalajel, the progress was driven by the Kingdom’s broader healthcare model, which seeks to improve quality of life through specialized care pathways.

 

Related Topics:

WHO URGES TO USE ASTRAZENECA VACCINE; 4 EU COUNTRIES HALT THE USE

INTERVIEW: Dr. Gehad Elkady on Hidden Cardiovascular Risks Facing HIV Patients

School Fitness Screenings: Saudi Arabia’s Drive to Build a Healthy Generation

Short link :

Related Stories

Back to top button